2026-05-13

The ground is shifting for compounding pharmacies

If you take compounded semaglutide or tirzepatide through a telehealth platform, the ground beneath you is shifting.

The FDA has been tightening the rules for 503A compounding pharmacies. For years, these pharmacies produced generic versions of GLP-1s by citing "shortage" of the branded product. That official shortage ended. Without a declared shortage, the legal argument that kept massive-scale compounding alive weakens every month.

Individual compounding — what a patient needs for specific, documented, clinically justified medical reasons — remains legal and will continue to exist. Mass compounding — the platform model that sells compounded semaglutide as a consumer product to thousands of patients per month — is closing down.

Clinics with real relationships with local 503A pharmacies, documenting prescriptions patient by patient, survive. The physician who justifies a specific formulation for clinical reasons. That is a much smaller and more expensive market.

Platform models that assume volume do not survive. Their unit economics assume scale. Scale requires mass justification. Mass justification is no longer legally safe.

Three paths for current patients: go back to branded products — Ozempic, Wegovy, Mounjaro, Zepbound — more expensive without insurance but with better coverage on some plans. Seek research-grade peptides — gray area, no clinical oversight, variable quality. Or stop.

What we are seeing: RUO vial prices have risen in recent weeks. Some reputable vendors have preemptively shut down. Others, without reputation, are taking advantage of the uncertainty.

We do not sell peptides. We have no conflict of interest. That allows us to tell you what others cannot: the ground is shifting, and the transition will not be comfortable for anyone.